Interpace Biosciences, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OID
Interpace Biosciences filed an amendment to its 2025 Annual Report to include required proxy statement disclosures.
OID
Interpace Biosciences reports a significant net income increase in 2025 driven by a tax benefit, despite an 18% revenue decline following the discontinuation of its PancraGEN test.
OID
Interpace Biosciences files an amendment to its 2024 Annual Report on Form 10-K to include information that was to be incorporated by reference from the company's definitive proxy statement.
OID
10-K: Interpace Biosciences Restates Financials Amid PancraGEN Uncertainty, Eyes Strategic Alternatives
Interpace Biosciences restates prior financial statements due to royalty accrual errors and navigates challenges including a potential non-coverage decision for its PancraGEN test.
OID
10-K/A: Interpace Biosciences Files Amended 10-K to Include Missing Proxy Information and Certifications
Interpace Biosciences has filed an amendment to its annual report on Form 10-K to include information that was to be incorporated by reference from the company's definitive proxy statement and additional certifications.
OID
Interpace Biosciences achieved profitability in 2023, reporting operating income of $2.8 million, while navigating regulatory challenges and strategic shifts.